Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

This year's JPMorgan health-care conference took place a month after UnitedHealthcare CEO Brian Thompson was fatally shot in ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Butler University's plans to renovate and expand Clowes Memorial Hall, including the addition of a ballroom space, aim to ...

Also in today’s newsletter, a record number of US companies weigh China exit, and Trump calls on Opec to push down global oil prices ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...